TotalMarketCap

Autolus Therapeutics

AUTLNasdaq United KingdomHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$332.703 M

$1.25 -9.42%

Close of 6 Nov 2026

As of 6 Nov 2026, Autolus Therapeutics (AUTL) has a market capitalization of $332.7M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$10.1M

#3128 by revenue

Earnings

-$287.5M

Loss-making

Shares outstanding

266,162,540

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #74TRex BioTRXB$355.7M
  2. #75IRulya TherapeuticsIRLA$335.1M
  3. #76Autolus TherapeuticsAUTL$332.7M
  4. #77AgomAb TherapeuticsAGMB$332.4M
  5. #78Fennec PharmaceuticalsFENC$327.6M

What if Autolus Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$106,088.84

Per share 84,871× higher

Bitcoin $1.53T

$5,740.28

Per share 4,592× higher

Apple $5.02T

$18,844.81

Per share 15,076× higher

Or at a round number

$500.0M$1.00B$2.00B$5.00B

Where these numbers come from

Share counts and financials for Autolus Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.